2-(2-chlorobenzamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-chlorobenzamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide
• 英文别名: 2-[(2-Chlorobenzoyl)amino]-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide；2-[(2-chlorobenzoyl)amino]-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide
• 化学式: C₁₅H₁₄ClN₃O₂S
• 分子量: 335.814
• InChiKey: JQGZXGVXUOAODE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2-chlorobenzamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide 、 氯化苄 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 以70.5%的产率得到6-benzyl-2-(2-chlorobenzamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide
  参考文献：
  名称：

  双靶向ERK1和ERK5抑制剂的制备及其抗肿瘤应用

  摘要：

  本发明涉及一种双靶向ERK1和ERK5的抑制剂制备及其应用，属于抗肿瘤药学技术领域。本发明解决的技术问题是提供一种作为双靶向ERK1和ERK5抑制剂的化合物。该化合物包括如下所示的化合物或其药学上可接受的盐。本发明的化合物或其药学上可接受的盐，可以作为ERK1和ERK5的抑制剂，具有抗肿瘤活性，能有效的抑制肿瘤细胞的生长。本发明化合物优选为抗肿瘤化合物，所对应肿瘤类型的特点为ERK1和/或ERK5高表达。

  公开号：

  CN111138449B
• 作为产物：
  描述：

  2-氨基-3-氨基甲酰-4,7-二氢-5H-噻吩并[2,3-c]吡啶-6-羧酸叔丁酯 在 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 10.0h， 生成 2-(2-chlorobenzamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide
  参考文献：
  名称：

  Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types

  摘要：

  ERK1 and ERK5 are proposed to have pivotal roles in several types of cancer. Under some circumstance, ERK5 may provide a common bypass route, which rescues proliferation upon abrogation of ERK1 signaling. Thus, we accurately classified the tumor types from The Cancer Genome Atlas (TCGA) based on the expression levels of ERK1 and ERK5. We proposed a novel therapeutic strategy to overcome the above-mentioned compensatory mechanism in specific tumor types by co-targeting both ERK1 and ERK5. On the basis of the idea of overcoming ERK5 compensation mechanism, 22ac (ADTL-EI1712) as the first selective dual-target inhibitor of ERK1 and ERK5 was discovered to have potent antitumor effects in vitro and in vivo. Interestingly, this compound was found to induce regulated cell death accompanied by autophagy in MKN-74 cells. Taken together, our results warrant the potential of this dual-target inhibitor as a new candidate drug that conquers compensatory mechanism in certain tumor types.

  DOI：

  10.1021/acs.jmedchem.9b01896

文献信息

• COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS
  申请人：Tait Bradley

  公开号：US20130072473A1

  公开（公告）日：2013-03-21

  The present invention is directed to compounds of Formulae (I), (IIa-IIh), (IIIa-IIIe), (IVa-IVc), (Va-V1), (VIa-VII), (VII), (VIII) and (IX), pharmaceutical compositions thereof and methods of use thereof in the treatment of conditions associated with a dysfunction in proteostasis.

  本发明涉及式(I)、(IIa-IIh)、(IIIa-IIIe)、(IVa-IVc)、(Va-V1)、(VIa-VII)、(VII)、(VIII)和(IX)化合物，以及其制备的药物组合物和治疗与蛋白质稳态失调相关疾病的方法。
• [EN] COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES DE REPLIEMENT DES PROTÉINES
  申请人：PROTEOSTASIS THERAPEUTICS INC

  公开号：WO2012154888A1

  公开（公告）日：2012-11-15

  The present invention is directed to compounds of Formulae (I), (Ila-IIh), (Illa- Ille), (IVa-IVc), (Va-Vl), (Via- VII), (VII), (VIII) and (IX), pharmaceutical compositions thereof and methods of use thereof in the treatment of conditions associated with a dysfunction in proteostasis.